Precision Oncology
We are setting the standard
At Variantyx, we are setting the standard of genome analysis and leading the way by offering the most comprehensive diagnostic testing clinically available for hereditary cancer predisposition. With thorough interrogation of the genome, we have the ability to detect all major clinically relevant variant types from one sample. A single, unified clinical report is generated through variant evaluation performed by clinical experts.
Using our methodology’s superior analytical and clinical validity, we are providing better overall performance and the most complete assessment of hereditary cancer risk. All with a single test, and a single cost.
Our methodology detects variants missed by others
Hereditary cancers are caused by a wide variety of DNA changes. Comprehensive detection of all major clinically relevant variant types requires the right technology. PCR-free whole genome sequencing (WGS) generates uniform coverage of >98% of the patient’s DNA. Compare that to PCR-based panel and exome technologies that remove and skew data, generating fragmented coverage of only 1-2% of the patient’s DNA.
Pairing WGS with our Genomic Intelligence® proprietary analytical software provides the most comprehensive variant detection available, sequencing and analyzing the entire gene. In comparison, most other hereditary cancer tests only sequence and analyze targeted regions of the gene, typically exons and selected intronic regions.
Our precision oncology portfolio
OncoAlly® hereditary cancer analyses focus on pre-curated sets of indication-relevant genes. With the full underlying genome data always available, we have the flexibility to add newly associated genes at any time.
